Treatment patterns, health care utilization, and costs of ovarian cancer in central and eastern europe using a delphi panel based on a retrospective chart review

Kun Kim, Emma Hernlund, Z. Hernádi, Janos Revesz, Imre Pete, Andras Szantho, Lubomir Bodnar, Rodoslaw BodnarMadry, Agnieszka Timorek-Lemieszczuk, Tatjana Bozanovic, Suzana Vasovic, Zorica Tomasevic, Milica Zivaljevic, Vladimir Pazin, Tomas Minarik, Hana Garanova, Lydia Helpianska, Nahila Justo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: Despite the considerable disease burden of ovarian cancer, there were no cost studies in Central and Eastern Europe. This study aimed to describe treatment patterns, health care utilization, and costs associated with treating ovarian cancer in Hungary, Poland, Serbia, and Slovakia. Method: Overall clinical practice for management of epithelial ovarian cancer was investigated through a 3-round Delphi panel. Experts completed a survey based on the chart review (n = 1542). The survey was developed based on clinical guidelines and the International Federation of Gynecology and Obstetrics Annual Report. Means, ranges, and outlier values were discussed with the experts during a telephone interview. Finally, consensus estimates were obtained in face-to-face workshops. Based on these results, overall cost of ovarian cancer was estimated using a Markov model. Results: The patients included in the chart review were followed up from presurgical diagnosis and in each phase of treatment, that is, surgical staging and primary surgery, chemotherapy and chemotherapy monitoring, follow-up, and palliative care. The 5-year overall cost per patient was ε14,100 to ε16,300 in Hungary, ε14,600 to ε15,800 in Poland, ε7600 to ε8100 in Serbia, and ε12,400 to ε14,500 in Slovakia. The main components were chemotherapy-associated costs (68%Y74% of the total cost), followed by cost of primary treatment with surgery (15%Y21%) and palliative care (3%Y10%). Conclusions: Patients with ovarian cancer consume considerable health care resources and incur substantial costs in Central and Eastern Europe. These findings may prove useful for clinicians and decision makers in understanding the economic implications of managing ovarian cancer in Central and Eastern Europe and the need for innovative therapies. ORIGINAL STUDY

Original languageEnglish
Pages (from-to)823-832
Number of pages10
JournalInternational Journal of Gynecological Cancer
Volume23
Issue number5
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Patient Acceptance of Health Care
Eastern Europe
Health Care Costs
Ovarian Neoplasms
Costs and Cost Analysis
Serbia
Slovakia
Hungary
Poland
Palliative Care
Drug Therapy
Therapeutics
Annual Reports
Aftercare
Investigational Therapies
Health Resources
Practice Management
Gynecology
Obstetrics
Economics

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Treatment patterns, health care utilization, and costs of ovarian cancer in central and eastern europe using a delphi panel based on a retrospective chart review. / Kim, Kun; Hernlund, Emma; Hernádi, Z.; Revesz, Janos; Pete, Imre; Szantho, Andras; Bodnar, Lubomir; BodnarMadry, Rodoslaw; Timorek-Lemieszczuk, Agnieszka; Bozanovic, Tatjana; Vasovic, Suzana; Tomasevic, Zorica; Zivaljevic, Milica; Pazin, Vladimir; Minarik, Tomas; Garanova, Hana; Helpianska, Lydia; Justo, Nahila.

In: International Journal of Gynecological Cancer, Vol. 23, No. 5, 06.2013, p. 823-832.

Research output: Contribution to journalArticle

Kim, K, Hernlund, E, Hernádi, Z, Revesz, J, Pete, I, Szantho, A, Bodnar, L, BodnarMadry, R, Timorek-Lemieszczuk, A, Bozanovic, T, Vasovic, S, Tomasevic, Z, Zivaljevic, M, Pazin, V, Minarik, T, Garanova, H, Helpianska, L & Justo, N 2013, 'Treatment patterns, health care utilization, and costs of ovarian cancer in central and eastern europe using a delphi panel based on a retrospective chart review', International Journal of Gynecological Cancer, vol. 23, no. 5, pp. 823-832. https://doi.org/10.1097/IGC.0b013e318291e8ca
Kim, Kun ; Hernlund, Emma ; Hernádi, Z. ; Revesz, Janos ; Pete, Imre ; Szantho, Andras ; Bodnar, Lubomir ; BodnarMadry, Rodoslaw ; Timorek-Lemieszczuk, Agnieszka ; Bozanovic, Tatjana ; Vasovic, Suzana ; Tomasevic, Zorica ; Zivaljevic, Milica ; Pazin, Vladimir ; Minarik, Tomas ; Garanova, Hana ; Helpianska, Lydia ; Justo, Nahila. / Treatment patterns, health care utilization, and costs of ovarian cancer in central and eastern europe using a delphi panel based on a retrospective chart review. In: International Journal of Gynecological Cancer. 2013 ; Vol. 23, No. 5. pp. 823-832.
@article{7ff13508e6a64c0a9cb239cb3b02867d,
title = "Treatment patterns, health care utilization, and costs of ovarian cancer in central and eastern europe using a delphi panel based on a retrospective chart review",
abstract = "Objective: Despite the considerable disease burden of ovarian cancer, there were no cost studies in Central and Eastern Europe. This study aimed to describe treatment patterns, health care utilization, and costs associated with treating ovarian cancer in Hungary, Poland, Serbia, and Slovakia. Method: Overall clinical practice for management of epithelial ovarian cancer was investigated through a 3-round Delphi panel. Experts completed a survey based on the chart review (n = 1542). The survey was developed based on clinical guidelines and the International Federation of Gynecology and Obstetrics Annual Report. Means, ranges, and outlier values were discussed with the experts during a telephone interview. Finally, consensus estimates were obtained in face-to-face workshops. Based on these results, overall cost of ovarian cancer was estimated using a Markov model. Results: The patients included in the chart review were followed up from presurgical diagnosis and in each phase of treatment, that is, surgical staging and primary surgery, chemotherapy and chemotherapy monitoring, follow-up, and palliative care. The 5-year overall cost per patient was ε14,100 to ε16,300 in Hungary, ε14,600 to ε15,800 in Poland, ε7600 to ε8100 in Serbia, and ε12,400 to ε14,500 in Slovakia. The main components were chemotherapy-associated costs (68{\%}Y74{\%} of the total cost), followed by cost of primary treatment with surgery (15{\%}Y21{\%}) and palliative care (3{\%}Y10{\%}). Conclusions: Patients with ovarian cancer consume considerable health care resources and incur substantial costs in Central and Eastern Europe. These findings may prove useful for clinicians and decision makers in understanding the economic implications of managing ovarian cancer in Central and Eastern Europe and the need for innovative therapies. ORIGINAL STUDY",
author = "Kun Kim and Emma Hernlund and Z. Hern{\'a}di and Janos Revesz and Imre Pete and Andras Szantho and Lubomir Bodnar and Rodoslaw BodnarMadry and Agnieszka Timorek-Lemieszczuk and Tatjana Bozanovic and Suzana Vasovic and Zorica Tomasevic and Milica Zivaljevic and Vladimir Pazin and Tomas Minarik and Hana Garanova and Lydia Helpianska and Nahila Justo",
year = "2013",
month = "6",
doi = "10.1097/IGC.0b013e318291e8ca",
language = "English",
volume = "23",
pages = "823--832",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Treatment patterns, health care utilization, and costs of ovarian cancer in central and eastern europe using a delphi panel based on a retrospective chart review

AU - Kim, Kun

AU - Hernlund, Emma

AU - Hernádi, Z.

AU - Revesz, Janos

AU - Pete, Imre

AU - Szantho, Andras

AU - Bodnar, Lubomir

AU - BodnarMadry, Rodoslaw

AU - Timorek-Lemieszczuk, Agnieszka

AU - Bozanovic, Tatjana

AU - Vasovic, Suzana

AU - Tomasevic, Zorica

AU - Zivaljevic, Milica

AU - Pazin, Vladimir

AU - Minarik, Tomas

AU - Garanova, Hana

AU - Helpianska, Lydia

AU - Justo, Nahila

PY - 2013/6

Y1 - 2013/6

N2 - Objective: Despite the considerable disease burden of ovarian cancer, there were no cost studies in Central and Eastern Europe. This study aimed to describe treatment patterns, health care utilization, and costs associated with treating ovarian cancer in Hungary, Poland, Serbia, and Slovakia. Method: Overall clinical practice for management of epithelial ovarian cancer was investigated through a 3-round Delphi panel. Experts completed a survey based on the chart review (n = 1542). The survey was developed based on clinical guidelines and the International Federation of Gynecology and Obstetrics Annual Report. Means, ranges, and outlier values were discussed with the experts during a telephone interview. Finally, consensus estimates were obtained in face-to-face workshops. Based on these results, overall cost of ovarian cancer was estimated using a Markov model. Results: The patients included in the chart review were followed up from presurgical diagnosis and in each phase of treatment, that is, surgical staging and primary surgery, chemotherapy and chemotherapy monitoring, follow-up, and palliative care. The 5-year overall cost per patient was ε14,100 to ε16,300 in Hungary, ε14,600 to ε15,800 in Poland, ε7600 to ε8100 in Serbia, and ε12,400 to ε14,500 in Slovakia. The main components were chemotherapy-associated costs (68%Y74% of the total cost), followed by cost of primary treatment with surgery (15%Y21%) and palliative care (3%Y10%). Conclusions: Patients with ovarian cancer consume considerable health care resources and incur substantial costs in Central and Eastern Europe. These findings may prove useful for clinicians and decision makers in understanding the economic implications of managing ovarian cancer in Central and Eastern Europe and the need for innovative therapies. ORIGINAL STUDY

AB - Objective: Despite the considerable disease burden of ovarian cancer, there were no cost studies in Central and Eastern Europe. This study aimed to describe treatment patterns, health care utilization, and costs associated with treating ovarian cancer in Hungary, Poland, Serbia, and Slovakia. Method: Overall clinical practice for management of epithelial ovarian cancer was investigated through a 3-round Delphi panel. Experts completed a survey based on the chart review (n = 1542). The survey was developed based on clinical guidelines and the International Federation of Gynecology and Obstetrics Annual Report. Means, ranges, and outlier values were discussed with the experts during a telephone interview. Finally, consensus estimates were obtained in face-to-face workshops. Based on these results, overall cost of ovarian cancer was estimated using a Markov model. Results: The patients included in the chart review were followed up from presurgical diagnosis and in each phase of treatment, that is, surgical staging and primary surgery, chemotherapy and chemotherapy monitoring, follow-up, and palliative care. The 5-year overall cost per patient was ε14,100 to ε16,300 in Hungary, ε14,600 to ε15,800 in Poland, ε7600 to ε8100 in Serbia, and ε12,400 to ε14,500 in Slovakia. The main components were chemotherapy-associated costs (68%Y74% of the total cost), followed by cost of primary treatment with surgery (15%Y21%) and palliative care (3%Y10%). Conclusions: Patients with ovarian cancer consume considerable health care resources and incur substantial costs in Central and Eastern Europe. These findings may prove useful for clinicians and decision makers in understanding the economic implications of managing ovarian cancer in Central and Eastern Europe and the need for innovative therapies. ORIGINAL STUDY

UR - http://www.scopus.com/inward/record.url?scp=84880422566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880422566&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e318291e8ca

DO - 10.1097/IGC.0b013e318291e8ca

M3 - Article

C2 - 23666016

AN - SCOPUS:84880422566

VL - 23

SP - 823

EP - 832

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5

ER -